glp 1 heart muscle GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential GLP-1 Receptor Agonists in Heart

5.Shorakae S, Teede H, de Courten B, Lambert G, Boyle J, Moran LJ

Biomarkers in the management of ulcerative colitis: a brief review

Novo Nordisk delivers advanced diabetes technology, focusing on innovation and the development of premium therapeutics

Recent reports regarding the use of the SGLT2 inhibitors as well as the new incretin-based therapies such as injectable glucagon-like peptide-1 (GLP-1) receptor agonists and oral inhibitors of dipeptidylpeptidase-4 (DPP-4) will be discussed

Liraglutide was approved in 2020 for use alongside lifestyle changes in pediatric patients 12 or older with a body weight over 60 kg (132 lbs.) and an initial BMI over 30